Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | CTRC | Q99895 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8243272 | 0.72 | — | — | |
| SCHEMBL242884 | 0.69 | PRSS1 (0.41) | SLC2A1PRSS1CTRCF2ALDH1A1 | |
| SCHEMBL8756026 | 0.65 | SLC2A1 (0.36) | SLC2A1PRSS1CTRCF2 | |
| SCHEMBL286578 | 0.64 | ALDH1A1 (0.47) | SLC2A1ALDH1A1 | |
| SCHEMBL8153153 | 0.64 | SLC2A1 (0.35) | SLC2A1 | |
| SCHEMBL8817632 | 0.64 | ALDH1A1 (0.47) | SLC2A1ALDH1A1 | |
| SCHEMBL8931106 | 0.64 | ALDH1A1 (0.47) | SLC2A1ALDH1A1 | |
| SCHEMBL3185827 | 0.64 | PRSS1 (0.38) | SLC2A1PRSS1CTRCF2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28389948 | 0.63 | ALDH1A1 (0.46) | SLC2A1ALDH1A1 | |
| SCHEMBL6403541 | 0.61 | ALDH1A1 (0.44) | SLC2A1PRSS1CTRCF2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071339-B2 | Process for preparing functionalized γ-butyrolactones from mucohalic acid | WARNER LAMBERT COMPANY LLC (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1537095-B1 | PROCESS FOR PREPARING FUNCTIONALIZED GAMMA-BUTYROLACTONES FROM MUCOHALIC ACID | WARNER LAMBERT CO (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1537095-A1 | PROCESS FOR PREPARING FUNCTIONALIZED -BUTYROLACTIONES FROM MUCOHALIC ACID | Warner-Lambert Company LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040049058-A1 | Process for preparing functionalized gamma-butyrolactiones from mucohalic acid | BELMONT DANIEL (US) | 2004-03-11 | — | — | US | disclosed |
| WO-2004020424-A1 | PROCESS FOR PREPARING FUNCTIONALIZED -BUTYROLACTIONES FROM MUCOHALIC ACID | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049058-A1 | Process for preparing functionalized gamma-butyrolactiones from mucohalic acid | MUC1, ALG1, ST3GAL3 | SLC2A1 4606/4885PRSS1 4050/4885CTRC 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.